Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678572 · ClinicalTrials.gov registry record · Phase 3
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
A Phase 3 study, sponsored by Delcath Systems.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT02678572 is a Phase 3 study that has completed, run by Delcath Systems. The registered enrollment target is 102 participants.
The verdict
NCT02678572, a Phase 3 study, has completed, sponsored by Delcath Systems.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.
Interventions
- COMBINATION_PRODUCT Melphalan/HDS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02678572
The ClinicalTrials.gov registry entry for NCT02678572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delcath Systems, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melphalan/HDS is the first listed.
NCT02678572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02678572 about?
NCT02678572 is a clinical study titled "Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma". This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients liv...
What is the current status of trial NCT02678572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2016-02-01. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT02678572?
The interventions under investigation include: Melphalan/HDS (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02678572?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.